Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails

▤ Summary

Bristol Myers Squibb faces pressure from its patent cliff and depends heavily on upcoming clinical trial results for milvexian. An analyst argues that a failed readout could intensify growth problems and revive merger speculation among large drugmakers. The article also reviews the company’s key revenue drugs, especially Eliquis and Opdivo, and explains how generics and biosimilars could erode sales. It highlights additional pipeline assets such as admilparant, Camzyos, Breyanzi, and Cobenfy as part of BMS’s broader growth strategy.

▦ Linked Companies